About Denintuzumab Mafodotin (SGN-CD19A; 19A)

SGN-CD19A is an antibody-drug conjugate (ADC) targeting CD19, a protein expressed broadly on B-cell malignancies. 19A is comprised of an anti-CD19 monoclonal antibody linked to a synthetic cell-killing agent, monomethyl auristatin F (MMAF). The ADC is designed to be stable in the bloodstream, and to release its cytotoxic agent upon internalization into CD19-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.


A phase 2 clinical trial is evaluating 19A in combination with chemotherapy for relapsed diffuse large B-cell lymphoma (DLBCL). A phase 2 trial in frontline DLBCL is planned for 2016.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave